Navigation Links
GenVec Appoints Cynthia Collins as President and CEO
Date:5/21/2012

GAITHERSBURG, Md., May 21, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ: GNVC) today announced that effective May 23, 2012 Cynthia Collins has been appointed as President and Chief Executive Officer. In addition, Ms. Collins is expected to be appointed to the Board of Directors of GenVec. Effective upon Ms. Collins' appointment, Paul H. Fischer, Ph.D. will step down as GenVec's President and CEO and as a member of the Board.  As announced in December, Dr. Fischer is retiring, having served as GenVec's President and CEO since 1996.

Ms. Collins previously served as Group Vice President, Cellular Analysis Business of Beckman Coulter from 2007 to until its sale in 2011. Prior to joining Beckman Coulter, Ms. Collins served as Chief Executive Officer of Sequoia Pharmaceuticals, Inc., a private biotechnology company developing antiviral drugs. Prior to joining Sequoia Pharmaceuticals, Ms. Collins served as President of Clinical Micro Sensors, Inc., a wholly owned subsidiary of Motorola where she directed the development and commercialization of molecular diagnostic microarray products and led the eventual strategic divestiture of the division. Before Motorola, she spent over 17 years at Baxter Healthcare in a variety of executive roles, including President of Global Oncology and Vice President of Strategy and Portfolio Management of BioScience. Prior to joining Baxter Healthcare, she worked six years with Abbott Laboratories in a series of operational assignments.

"Cindy brings to the company substantial business, strategic, and leadership experience within the health care industry and we are pleased to welcome her as GenVec's President and CEO," said Zola P. Horovitz, Ph.D, Chairman of the Board of Directors of GenVec. "This transition will allow the organization to build on the strong scientific and financial foundation that the Company has developed under Dr. Fischer's leadership."

"I am excited to be joining GenVec at this very important time in the Company's history," said Cynthia Collins. "I look forward to working with the Board and the rest of the management team to maximize the value of our product pipeline and related technologies. GenVec's novel treatment for hearing loss and balance disorders, partnered with Novartis AG, is on its path towards the commencement of human clinical trials and we will work together to see that our human and animal vaccine programs continue to progress.  We will also continue the sound strategy of partnering selected programs to maintain GenVec's strong financial position."

Ms. Collins received her undergraduate degree in microbiology in 1980 from the University of Illinois and her Masters in Business Administration from the University of Chicago Graduate School of Business in 1988.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (FMD). Additional information about GenVec is available at www.genvec.com and in the Company's various filings with the Securities and Exchange Commission.

Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding funding, grants, collaborations, revenues, cash burn rates, the development of products and the success of the Company's collaborations, including with Novartis and Merial, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act.  GenVec cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating to the early stage of GenVec's product candidates under development; uncertainties relating to research and development activities; risks relating to the commercialization, if any, of GenVec's proposed product candidates; dependence on the efforts of collaborators and third parties; dependence on intellectual property; currently unanticipated expenses, and risks that we may lack the financial resources and access to capital to fund our operations.  Further information on the factors and risks that could affect GenVec's business, financial conditions and results of operations, are contained in GenVec's filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov.  These forward-looking statements speak only as of the date of this press release, and GenVec assumes no duty to update forward-looking statements.Retail Investor and Media Contact:Institutional Investor Contact:GenVec, Inc. 

S.A. Noonan CommunicationsDouglas J. Swirsky 

Susan A. Noonan(240) 632-55(212) 966-3650dswirsky@genvec.com 

susan@sanoonan.com 


'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Announces Multiple Presentations at the American Society of Tropical Medicine and Hygiene Meeting
2. GenVec Receives National Cancer Institute Grant to Expand Cancer Program
3. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
4. GenVec Reports Third Quarter 2010 Financial Results
5. GenVec Forms Collaboration With World-Leading Animal Health Company
6. GenVec Reports Fourth Quarter and 2010 Year-End Financial Results
7. GenVec to Host First Quarter 2011 Earnings Call and Webcast
8. GenVec Elects Adel A.F. Mahmoud and Edward M. Connor, Jr. to Board of Directors
9. GenVec Reports Second Quarter 2011 Financial Results
10. GenVec to Present at Stifel Nicolaus 2011 Healthcare Conference
11. GenVec to Release Third Quarter 2011 Financial Results and Conduct a Conference Call on November 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... WASHINGTON , Sept. 8, 2017 ... Mobile MRI Unit coming to Washington DC ... When: Tuesday, September 12 th – Monday, ... to Washington, D.C. offering free MRI brain scans to the public.Where:  ... – will be parked at 501 K Street NW, Washington, D.C.What:BTF brings ...
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... 7, 2017   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade cell and tissue hypothermic storage ... Mike Rice , President and CEO, will be presenting at ... Rodman & Renshaw 19 th Annual Global Investment Conference ... p.m. Pacific time). The conference is being held at the ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... As part of The ... unveiled a redesigned website. The new site – still located at http://www.garlandco.com ... contractors and other industry users that Garland serves. , After an ambitious phase ...
(Date:9/20/2017)... ... September 20, 2017 , ... The Honey Pot Company is ... goal is to ignite conversation via social media and word-of-mouth regarding vaginal health, ... declared September “Humans with Vaginas” month, releasing a video celebrating the power of ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... Health & ... and 30-Hour and HAZWOPER 8-, 24- and 40-Hour courses from now until November 30, ... In addition to offering these discounted prices to all businesses and government agencies – ...
(Date:9/20/2017)... ... ... “Finn Mouseson”: follows the exciting story of a mouse as the need for ... a journey that will show that friends are to be gathered but home is ... illustrator, Melody Gersonde-Mickelson, who has earned a bachelor’s degree in Fine Arts from the ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “The Foggy Road to Moorwick”: the adventures ... Moorwick” is the creation of published author, Jeanine Liston, a busy mother of five who ... , “I have been writing this book for over twenty years. It was a ...
Breaking Medicine News(10 mins):